April 5, 2019
The Japan arm of UK-based pharmaceutical company Clinigen Group said on April 4 that it has obtained exclusive rights from South Korea’s biopharmaceutical company GC Pharma to develop and commercialize the intracerebroventricular (ICV) formulation of the Hunter syndrome treatment idursulfase...read more